Aclaris Therapeutics(DE:8AT)
€3.76+0.28 (+7.96%)
DE:8AT
Aclaris Therapeutics stock forecast
€3.76
At close:+0.28 (+7.96%)
Aclaris Therapeutics (8AT) Stock Forecast & Price Target
1 Followers
8AT Analyst Ratings
Strong Buy
8Buy0Hold0Sell
Based on 8 analysts giving stock ratings to Aclaris Therapeutics in the past 3 months
8AT Stock 12 Month Forecast
Average Price Target
€10.36▲(175.77% Upside)Based on 8 Wall Street analysts offering 12 month price targets for Aclaris Therapeutics in the last 3 months. The average price target is EUR 10.36 with a high forecast of EUR 14.42 and a low forecast of EUR 7.21. The average price target represents a 175.77% change from the last price of EUR 3.76.
Past 12 Months12 Month ForecastJan2026Oct2026
High€14.42
Average€10.36
Low€7.21
Highest Price TargetHighest€14.42Average Price Target€10.36Lowest Price TargetLowest€7.21
Detailed List of Analyst Forecasts​
Analyst Type
Ranks
Analyst Rating
Upside/ Downside
Action
| Price Target | Article | |||||||
|---|---|---|---|---|---|---|---|---|
| Ram Selvaraju | H.C. Wainwright | €14.42 | buy | 283.68%Upside | Reiterated | 11/09/26 | ||
| Edward Nash | Canaccord Genuity | €11.72 | buy | 211.74%Upside | Reiterated | 11/06/26 | ||
 Unknown AnalystNot Ranked | Oppenheimer | €9.01 | buy | 139.80%Upside | Reiterated | 11/06/26 | ||
| Martin Fan | Wedbush | €7.21 | buy | 91.84%Upside | Reiterated | 11/06/26 | ||
| Adam Vogel | Craig-Hallum | €9.01→€8.11 | buy | 115.82%Upside | Reiterated | 10/28/26 | ||
| Seamus Fernandez | Guggenheim | €10.81 | buy | 187.76%Upside | Reiterated | 10/28/26 | ||
| Biren Amin | Piper Sandler | €9.91 | buy | 163.78%Upside | Reiterated | 10/19/26 | ||
| Kate Dellorusso | LifeSci Capital | €11.72 | buy | 211.74%Upside | Reiterated | 10/01/26 | ||
| Alex Thompson CFA | Stifel Nicolaus | €3.60 | hold | -4.08%Downside | Reiterated | 05/08/26 | ||
| Unknown AnalystNot Ranked | Goldman Sachs | €9.01 | buy | 139.80%Upside | Reiterated | 04/16/26 |
| Rating | Article | ||||
|---|---|---|---|---|---|
| Ram SelvarajuH.C. Wainwright | BuyReiterated€14.42 | 11/09/26 | 283.68%Upside | ||
| Edward NashCanaccord Genuity | BuyReiterated€11.72 | 11/06/26 | 211.74%Upside | ||
| Unknown AnalystOppenheimerNot Ranked | BuyReiterated€9.01 | 11/06/26 | 139.80%Upside | ||
| Martin FanWedbush | BuyReiterated€7.21 | 11/06/26 | 91.84%Upside | ||
| Adam VogelCraig-Hallum | BuyReiterated€9.01→€8.11 | 10/28/26 | 115.82%Upside | ||
| Seamus FernandezGuggenheim | BuyReiterated€10.81 | 10/28/26 | 187.76%Upside | ||
| Biren AminPiper Sandler | BuyReiterated€9.91 | 10/19/26 | 163.78%Upside | ||
| Kate DellorussoLifeSci Capital | BuyReiterated€11.72 | 10/01/26 | 211.74%Upside | ||
| Alex Thompson CFAStifel Nicolaus | HoldReiterated€3.60 | 05/08/26 | -4.08%Downside | ||
| Unknown AnalystGoldman SachsNot Ranked | BuyReiterated€9.01 | 04/16/26 | 139.80%Upside |
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Best Analysts Covering Aclaris Therapeutics
3 Months
Success Rate7/7 ratings generated profit
100%
Average Return
+29.89%
Copying Martin Fan's trades and holding each position for 3 Months would result in 100.00% of your transactions generating a profit, with an average return of +29.89% per trade.
1 Year
Success Rate11/13 ratings generated profit
85%
Average Return
+67.23%
Copying Ram Selvaraju's trades and holding each position for 1 Year would result in 84.62% of your transactions generating a profit, with an average return of +67.23% per trade.
2 Years
Success Rate11/13 ratings generated profit
85%
Average Return
+58.70%
Copying Ram Selvaraju's trades and holding each position for 2 Years would result in 84.62% of your transactions generating a profit, with an average return of +58.70% per trade.
8AT Analyst Recommendation Trends
| Rating | Jul 26 | Aug 26 | Sep 26 | Oct 26 | Nov 26 |
|---|---|---|---|---|---|
| Strong Buy | 10 | 7 | 7 | 14 | 13 |
| Buy | 0 | 0 | 0 | 0 | 0 |
| Hold | 1 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 |
| total | 11 | 7 | 7 | 14 | 13 |
In the current month, 8AT has received 13 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. 8AT average Analyst price target in the past 3 months is 10.36.
8AT Financial Forecast
High€-0.11
Consensus€-0.14
Low€-0.23
8AT Earnings Forecast
Next quarter’s earnings estimate for 8AT is -EUR 0.14 with a range of -EUR 0.23 to -EUR 0.11. The previous quarter’s EPS was -EUR 0.11. Its overall industry beat the EPS estimate 57.80% of the time in the past 12 months.
High€2.43M
Consensus€1.24M
Low€0.00
8AT Sales Forecast
Next quarter’s sales forecast for 8AT is EUR 1.24M with a range of EUR 0 to EUR 2.43M. The previous quarter’s sales results were EUR 1.33M. Its overall industry beat sales estimates 50.04% of the time in the past 12 months.
8AT Stock Forecast FAQ
What is DE:8AT’s average 12-month price target, according to analysts?
Based on analyst ratings, Aclaris Therapeutics’s 12-month average price target is €10.36.
What is DE:8AT’s upside potential, based on the analysts’ average price target?
Aclaris Therapeutics has 175.77% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is Aclaris Therapeutics a Buy, Sell or Hold?
Aclaris Therapeutics has a consensus rating of Strong Buy, which is based on 8 buy ratings, 0 hold ratings and 0 sell ratings.
What is Aclaris Therapeutics’s share price target?
The average share price target for Aclaris Therapeutics is €10.36. This is based on 8 Wall Street analysts’ 12-month price targets, issued in the past 3 months. The highest analyst share price target is €14.42, and the lowest forecast is €7.21. The average share price target represents a 175.77% increase from the current price of €3.758.
What do analysts say about Aclaris Therapeutics?
Aclaris Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 8 Wall Street analysts.
How can I buy shares of Aclaris Therapeutics?
To buy shares of DE:8AT, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.
